SCHEMBL4476919

SCHEMBL4476919

CCc1cc(CC)c2c(C#N)c(/C=C/C(=O)Nc3ccncc3)n(C3CCc4ccccc43)c2n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CCNC P24863 1/20 0.31
CDK8 P49336 1/20 0.31
NPY1R P25929 1/20 0.31
MAPT P10636 2/20 0.31
POLB P06746 1/20 0.31
KDM4E B2RXH2 2/20 0.30
ALDH1A1 P00352 2/20 0.30
HPGD P15428 2/20 0.30
TRPV1 Q8NER1 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476927 1.00 KCNA5 (0.33) KCNA5CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4476302 0.92 RAB9A (0.36) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4476297 0.92 RAB9A (0.36) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4470424 0.87 CMA1 (0.35) CMA1AGTR1PPARG
SCHEMBL4470416 0.87 CMA1 (0.35) CMA1AGTR1PPARG
SCHEMBL4486655 0.82 CCR2 (0.33) CYP1A2CYP2C9CYP2C19HPGDTRPV1
SCHEMBL4486658 0.82 CCR2 (0.33) CYP1A2CYP2C9CYP2C19HPGDTRPV1
SCHEMBL4486440 0.82 AGTR1 (0.34) KDM4ECMA1AGTR1PPARG
SCHEMBL4480230 0.82 ALDH1A1 (0.36) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4480220 0.82 ALDH1A1 (0.36) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582651-B2 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-01 US disclosed
US-20060167038-A1 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
EP-1535922-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167038-A1 Pyrrolopyridine derivative and use thereof OPRD1, TRPV1, OPRM1 KCNA5 118/4885CYP1A2 936/4885CYP3A4 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.